Galmed Pharmaceuticals Ltd.
EOCN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001595353
No open-market purchases or sales by Galmed Pharmaceuticals Ltd. insiders were filed in the last 90 days; 14 institutions reported holding it in 13F filings for Q2 2026, worth $85.9K in total; no superinvestor holds it.
Holders of 5% or more of EOCN
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Galmed Pharmaceuticals Ltd., largest stake first. The change is against the holder's previous filing.
No holder currently reports owning 5% or more of Galmed Pharmaceuticals Ltd. on Schedule 13D or 13G.
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
19 Schedule 13D and 13G filings on Galmed Pharmaceuticals Ltd., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Nov 7, 20254:51 PM ET | CVI Investments, Inc.and 1 other | 13G/A | 3.10%173.3K shares | −4.00 ppfrom 7.10%Below 5% | Sep 30, 2025 | SEC |
| Aug 14, 20252:01 PM ET | CVI Investments, Inc.and 1 other | 13G/A | 7.10%173.3K shares | – | Jun 30, 2025 | SEC |
| Feb 18, 20254:15 PM ET | Baharaff Allen | 13G/A | 2.60%44.1K shares | –Below 5% | Dec 31, 2024 | SEC |
| Nov 14, 2024 | CVI Investments, Inc. | 13G/AOld format | – | – | – | SEC |
| Sep 20, 2024 | Otsuka Masaya | 13G/AOld format | – | – | – | SEC |
| Sep 20, 2024 | Otsuka Masaya | 13GOld format | – | New | – | SEC |
| Feb 14, 2024 | CVI Investments, Inc. | 13G/AOld format | – | – | – | SEC |
| Feb 14, 2024 | Biotechnology Value Fund L P | 13G/AOld format | – | – | – | SEC |
| Feb 12, 2024 | Baharaff Allen | 13G/AOld format | – | – | – | SEC |
| Jul 21, 2023 | CVI Investments, Inc. | 13GOld format | – | New | – | SEC |
| Feb 14, 2023 | Biotechnology Value Fund L P | 13G/AOld format | – | – | – | SEC |
| Feb 7, 2023 | Baharaff Allen | 13G/AOld format | – | – | – | SEC |
| Feb 14, 2022 | Nantahala Capital Management, LLC | 13G/AOld format | – | – | – | SEC |
| Feb 11, 2022 | Baharaff Allen | 13G/AOld format | – | – | – | SEC |
| Jan 27, 2022 | Ibex Investors LLC | 13G/AOld format | – | – | – | SEC |
| Feb 16, 2021 | Nantahala Capital Management, LLC | 13GOld format | – | New | – | SEC |
| Feb 12, 2021 | Baharaff Allen | 13G/AOld format | – | – | – | SEC |
| Feb 12, 2021 | Biotechnology Value Fund L P | 13G/AOld format | – | – | – | SEC |
| Jan 15, 2021 | Ibex Investors LLC | 13G/AOld format | – | – | – | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Galmed Pharmaceuticals Ltd. shares.
No Form 144 notices for Galmed Pharmaceuticals Ltd. are on file.